Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Science & Co

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Science & Co
Site position #84

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 72.9/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +18
92
74
Dose & formulationCoreAge Rx +14
88
74
Clinical oversightCoreAge Rx +17
93
76
Labs & monitoringCoreAge Rx +35
90
55
FulfillmentCoreAge Rx +15
95
80
Contract termsScience & Co +15
67
82
CoreAge Rx · top barScience & Co · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxScience & Co
WeighScore89.5/10072.9/100
GradeB+C
Site position#1#84
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$149/mo month-to-month ($79 only on a 12-month plan)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$199/mo month-to-month ($125 only on a 12-month plan)
CoverageUS only; therapy-specific state restrictions applyNot publicly listed
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Science & Co

Site position #84 · C

Strengths

  • States twice in its footer that "Science and Co, Inc. is not a 503A or 503B compounding facility"
  • Its own FAQ names the commitment behind the headline: "Plans start at $125 a month on the 12 month plan"
  • The printed saving corroborates the reference price — 125 divided by 199 is 63%, exactly the "Save 37%" shown
  • "Same Price, Any Dose", with no hidden fees, no monthly membership and free shipping stated in the FAQ
  • Names its operating entity and state of incorporation, and says every batch is third-party tested

What to consider

  • The number it leads with is a twelve-month commitment; the per-month rates are $149 and $199
  • Only two figures are published per drug, so a three- or six-month plan cannot be priced without starting an intake
  • It says it is not a compounding facility but never names the pharmacy that is
  • No lab or monitoring protocol is published
  • Injection only on the pages read — no oral route and no brand lane

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard